Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pozelimab and Cemdisiran Combination in PNH Switching from Eculizumab
NCT04888507Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- May 2022
- Modality
- Antisense DNA, Recombinant Proteins and Enzymes, Conjugated siRNA
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pozelimab and cemdisiran in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Treatment-emergent Adverse Events at Day 225. Started Jul 2021; status: completed.
02
Drugs
pozelimabcemdisiran
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT04888507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04888507.